Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.49 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31345632 | 1.00 | ALDH1A1 (0.57) | ALDH1A1LMNAMAPTL3MBTL1GAA | |
| SCHEMBL4699958 | 0.92 | ALDH1A1 (0.55) | ALDH1A1LMNAMAPTL3MBTL1GAA | |
| SCHEMBL29140575 | 0.89 | ALDH1A1 (0.52) | ALDH1A1LMNAMAPTL3MBTL1GAA | |
| SCHEMBL30638389 | 0.89 | ALDH1A1 (0.52) | ALDH1A1LMNAMAPTL3MBTL1GAA | |
| SCHEMBL8108859 | 0.85 | POLB (0.51) | ALDH1A1LMNAMAPTL3MBTL1GAA | |
| SCHEMBL6306443 | 0.84 | KDM4E (0.45) | ALDH1A1LMNAMAPTGAAPOLB | |
| SCHEMBL6161066 | 0.83 | ALOX15 (0.69) | ALDH1A1LMNAMAPTL3MBTL1GAA | |
| SCHEMBL2312725 | 0.83 | ALDH1A1 (0.55) | ALDH1A1LMNAMAPTL3MBTL1GAA | |
| SCHEMBL8888591 | 0.83 | ALDH1A1 (0.57) | ALDH1A1LMNAMAPTL3MBTL1GAA | |
| SCHEMBL832201 | 0.81 | ALOX15 (0.69) | ALDH1A1LMNAMAPTL3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119585247-A | Bicyclic heterocyclic amide inhibitors of nav1.8 for the treatment of pain | 赛特温治疗公司 | 2025-03-07 | — | — | CN | disclosed |
| EP-4514789-A1 | <SUP2/>? <SUB2/>?V?BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA1.8 FOR THE TREATMENT OF PAIN | SiteOne Therapeutics, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023211990-A1 | BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA V1.8 FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023211990-A1 | BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA V1.8 FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-8288549-B2 | Glycine B antagonist | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-10-16 | — | — | US | disclosed |
| US-20110190342-A1 | GLYCINE B ANTAGONIST | HENRICH MARKUS | 2011-08-04 | — | — | US | disclosed |
| EP-2350014-A1 | GLYCINE B ANTAGONISTS | Merz Pharma GmbH & Co. KGaA (DE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010037533-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO KGAA (DE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190342-A1 | GLYCINE B ANTAGONIST | GRIN2B, GLRB, GRIN2A | ALDH1A1 4071/4885LMNA 2439/4885MAPT 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.